Abstract
The endogenous peptides endomorphin 1 and 2 are newly discovered, potent, selective mu-opioid receptor agonists. In the present study, we investigated responses to the endomorphin peptides in the systemic vascular bed of the anesthetized mouse. Endomorphin 1 and 2 induced dose-related decreases in mean arterial pressure when injected in doses of 3-100 nmol/kg i.v. Mean arterial pressure decreased 14 +/- 4, 23 +/- 4, and 42 +/- 5 mm Hg at the 10, 30, and 100 nmol/kg doses, respectively, of endomorphin 1 (n = 5-7; p < 0.05), and similar changes were observed in response to endomorphin 2. In terms of relative vasodepressor activity, endomorphin 1 and 2 were about equipotent and about threefold more potent than the mu-opioid selective agonist PL017 in decreasing mean arterial pressure; all three peptides decreased heart rate. The time-course of the vasodepressor responses to endomorphin 1 and 2 were similar in rate of onset and decay. Vasodepressor responses to endomorphin 1 and 2 and PL017 but not to nociceptin were inhibited by the opioid receptor antagonist naloxone in a dose of 2 mg/kg i.v. When compared in the mouse and rat, the relative decreases in systemic arterial pressure in response to i.v. injections of endomorphin 1 an...Continue Reading
References
May 1, 1985·Progress in Cardiovascular Diseases·M W JohnsonC S Wilcox
Jan 1, 1983·Annual Review of Pharmacology and Toxicology·J W Holaday
Apr 3, 1997·Nature·D Julius
Apr 3, 1997·Nature·J E ZadinaA J Kastin
Jan 1, 1997·Peptides·H C ChampionP J Kadowitz
Jan 1, 1997·Life Sciences·H C ChampionP J Kadowitz
Jan 1, 1997·Peptides·L HacklerA J Kastin
Mar 31, 1998·Life Sciences·M A CzaplaP J Kadowitz
Citations
Sep 5, 2002·European Journal of Pharmacology·Aly M Abdelrahman, Catherine C Y Pang
Jan 5, 2000·Life Sciences·G HorvathG Benedek
May 5, 2001·Pharmacology & Therapeutics·G Horvath
Mar 4, 2000·Peptides·A L VaccarinoA J Kastin
Mar 22, 2002·Clinical and Experimental Pharmacology & Physiology·Hunter C ChampionPhilip J Kadowitz
Mar 11, 2000·The European Journal of Neuroscience·K MonoryA Borsodi
Apr 26, 2011·Neuropeptides·J B FregonezeE De Castro E Silva
Dec 22, 2009·Diabetes Research and Clinical Practice·Fang-zhen XiaLi-juan Zhao
Jun 13, 2009·Peptides·Chang-lin WangRui Wang
Nov 9, 2007·Peptides·Weihong Pan, Abba J Kastin
Nov 21, 2007·Neuropeptides·Chang-lin WangRui Wang
Jul 14, 2007·European Journal of Pharmacology·Cai-Yun FuRui Wang
Feb 20, 2007·Peptides·Chang-Lin WangRui Wang
Feb 6, 2007·Peptides·Ye YuRui Wang
Dec 18, 2007·Chemistry & Biodiversity·Balázs Leitgeb
Aug 12, 2006·Peptides·Ye YuRui Wang
Mar 28, 2006·Peptides·Ye YuRui Wang
Sep 6, 2005·Peptides·Ye YuRui Wang
May 15, 2013·Journal of Diabetes Research·Jing LiuQian Guo
Jun 28, 2008·European Journal of Pharmacology·Zi-Qing KongRui Wang
Sep 1, 2016·Journal of Diabetes Research·Juan ZhaoRuilan Niu
Sep 13, 2005·Neuroscience·M B SilvermanS A Aicher
Jul 13, 2002·The Journal of Comparative Neurology·James F PeoplesElisabeth J Van Bockstaele
Mar 3, 2007·Pharmacological Reviews·Jakub FichnaJean-Claude Do Rego
Jan 25, 2000·American Journal of Physiology. Heart and Circulatory Physiology·H C ChampionA L Hyman
Aug 20, 2002·Japanese Journal of Pharmacology·Shinobu SakuradaMasayuki Yuhki